JP7778477B2 - セピアプテリンの薬学的に許容される塩 - Google Patents
セピアプテリンの薬学的に許容される塩Info
- Publication number
- JP7778477B2 JP7778477B2 JP2020566701A JP2020566701A JP7778477B2 JP 7778477 B2 JP7778477 B2 JP 7778477B2 JP 2020566701 A JP2020566701 A JP 2020566701A JP 2020566701 A JP2020566701 A JP 2020566701A JP 7778477 B2 JP7778477 B2 JP 7778477B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- salt
- subject
- less
- sepiapterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024030700A JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US62/678,025 | 2018-05-30 | ||
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US62/726,612 | 2018-09-04 | ||
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| US62/822,336 | 2019-03-22 | ||
| GC201937661 | 2019-05-28 | ||
| GC2019/37661 | 2019-05-28 | ||
| PCT/US2019/034505 WO2019232120A1 (en) | 2018-05-30 | 2019-05-30 | Pharmaceutically acceptable salts of sepiapterin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030700A Division JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527031A JP2021527031A (ja) | 2021-10-11 |
| JPWO2019232120A5 JPWO2019232120A5 (https=) | 2022-06-07 |
| JP2021527031A5 JP2021527031A5 (https=) | 2022-06-07 |
| JP7778477B2 true JP7778477B2 (ja) | 2025-12-02 |
Family
ID=68699017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Active JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
| JP2024030700A Active JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024030700A Active JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210269443A1 (https=) |
| EP (1) | EP3807279B1 (https=) |
| JP (2) | JP7778477B2 (https=) |
| KR (1) | KR20210038848A (https=) |
| CN (1) | CN112543758A (https=) |
| AU (2) | AU2019277372B2 (https=) |
| BR (1) | BR112020024332A2 (https=) |
| CA (1) | CA3102070A1 (https=) |
| CL (1) | CL2020003101A1 (https=) |
| CO (1) | CO2020016582A2 (https=) |
| IL (1) | IL279101A (https=) |
| MX (1) | MX2020012978A (https=) |
| WO (1) | WO2019232120A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024063143A (ja) * | 2018-05-30 | 2024-05-10 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| EP3801536B1 (en) | 2018-05-30 | 2024-07-17 | PTC Therapeutics MP, Inc. | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| CN112654356A (zh) * | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| JP2024506336A (ja) | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | 膠芽腫の治療方法 |
| EP4291196A1 (en) | 2021-02-09 | 2023-12-20 | PTC Therapeutics MP, Inc. | Methods for treating covid-19 with sepiapterin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523708A (ja) | 2007-04-11 | 2010-07-15 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法 |
| WO2011132435A1 (ja) | 2010-04-22 | 2011-10-27 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| ATE218345T1 (de) * | 1994-08-05 | 2002-06-15 | Suntory Ltd | Arzneimittel gegen spinocerebellare degeneration |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| IN2014DN09053A (https=) | 2012-05-07 | 2015-05-22 | Shiratori Pharm | |
| WO2017218421A1 (en) * | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| US11130760B2 (en) * | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| US11072614B2 (en) * | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2019
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 US US17/059,887 patent/US20210269443A1/en active Pending
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523708A (ja) | 2007-04-11 | 2010-07-15 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法 |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| WO2011132435A1 (ja) | 2010-04-22 | 2011-10-27 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
Non-Patent Citations (3)
| Title |
|---|
| ORGANIC PROCESS RESEARCH & DEVELOPMENT,2000,Vol.4,No.5,p.427-435 |
| 長瀬博監訳,最新 創薬化学 下巻,株式会社テクノミック,1999年9月25日,p.347-365 |
| 高田則幸,PHARM STAGE,2007年,Vol.6, No.10,p.20-25 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024063143A (ja) * | 2018-05-30 | 2024-05-10 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
| JP7841008B2 (ja) | 2018-05-30 | 2026-04-06 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | セピアプテリンの薬学的に許容される塩 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019277372A1 (en) | 2021-01-21 |
| EP3807279A4 (en) | 2022-04-06 |
| CL2020003101A1 (es) | 2021-05-14 |
| CA3102070A1 (en) | 2019-12-05 |
| IL279101A (en) | 2021-01-31 |
| AU2025201002A1 (en) | 2025-03-06 |
| CN112543758A (zh) | 2021-03-23 |
| WO2019232120A1 (en) | 2019-12-05 |
| JP7841008B2 (ja) | 2026-04-06 |
| EP3807279B1 (en) | 2025-12-31 |
| JP2021527031A (ja) | 2021-10-11 |
| US20210269443A1 (en) | 2021-09-02 |
| KR20210038848A (ko) | 2021-04-08 |
| MX2020012978A (es) | 2021-04-28 |
| CO2020016582A2 (es) | 2021-04-08 |
| BR112020024332A2 (pt) | 2021-02-23 |
| AU2019277372B2 (en) | 2024-12-19 |
| EP3807279A1 (en) | 2021-04-21 |
| JP2024063143A (ja) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7778477B2 (ja) | セピアプテリンの薬学的に許容される塩 | |
| US12213982B2 (en) | Pharmaceutical compositions comprising sepiapterin and uses thereof | |
| JP7502197B2 (ja) | セピアプテリン血漿曝露を増加させるための方法 | |
| JP7547215B2 (ja) | テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 | |
| HK40087700A (zh) | 墨蝶呤的药学上可接受的盐 | |
| EA049074B1 (ru) | Фармацевтически приемлемые соли сепиаптерина | |
| EA042976B1 (ru) | Фармацевтически приемлемые соли сепиаптерина | |
| BR112020003865B1 (pt) | Composições farmacêuticas compreendendo sepiapterina e usos das mesmas | |
| BR122024013534A2 (pt) | Sais e cocristais farmaceuticamente aceitáveis de sepiapterina, composição farmacêutica compreendendo os mesmos, e seus usos | |
| HK40119071A (en) | Methods for increasing sepiapterin plasma exposure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220530 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230830 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240305 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7778477 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |